P y reported Q3 2025 financial results today. Join us for a conference call and webcast where the $CHRS executive team will discuss Q3 2025 financial results and recent business highlights starting at 5 pm ET. Webcast: bit.ly/47jYekQ
Coherus Oncology
@Coherus_Bio
Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of immunotherapies to treat cancer.
174 Following 3.8K Followers 696 Posts
Latest posts 5
Coherus Oncology will report Q3 2025 financial results on November 6, 2025. Starting at 5 pm EDT, the $CHRS executive team will host a conference call and webcast to discuss Q3 2025 financial results and recent business highlights. Webcast: bit.ly/47jYekQ
Coherus Oncology is attending the following Investor Conferences in November and December. For webcast links of our presentations, please visit: bit.ly/4nhV8EB
To schedule 1:1 meetings during the conference, please reach out to your respective bank representative.
To schedule 1:1 meetings during the conference, please reach out to your respective bank representative.
Attending Opal Group's Family Office and Private Wealth Management Forum? Don't miss Coherus Oncology's CEO Denny Lanfear's presentation tomorrow and meet with the Coherus Oncology team.
We are excited to participate in SITC’s Targets for Cancer IO webinar and discuss CCR8 as a therapeutic target in oncology and share our clinical experience with CHS-114, our highly selective cytolytic anti-CCR8 mAb. Register to attend: bit.ly/3VEkGjx
Tune in on Oct. 22 for our Development of Anti-CCR8 Ab - Mechanisms and Clinical Results Webinar! We will address the novel therapeutic target C-C chemokine receptor 8 (CCR8), its role in regulatory T cell (Treg) activity and immunosuppression.View quoted post on X
Register: sitcancer.org/edu/webinars/t…